



UNIVERSITI PUTRA MALAYSIA

SYNTHESIS, IN-VITRO BIOACTIVITY EVALUATION AND MOLECULAR DOCKING OF MONOSACCHARIDE ESTER AND FATTY ACID AMIDE DERIVATIVES OF 5-AMINOSALICYLIC ACID

SAMIRA YOUSEFI

FS 2016 8



**SYNTHESIS, IN-VITRO BIOACTIVITY EVALUATION AND MOLECULAR
DOCKING OF MONOSACCHARIDE ESTER AND FATTY ACID AMIDE
DERIVATIVES OF 5-AMINOSALICYLIC ACID**

By

SAMIRA YOUSEFI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

May 2016

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



DEDICATION

“To my beloved parents, brother and grand parents, for their unconditional love, patience and support, which made this journey possible for me.”



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

SYNTHESIS, IN-VITRO BIOACTIVITY EVALUATION AND MOLECULAR DOCKING OF MONOSACCHARIDE ESTER AND FATTY ACID AMIDE DERIVATIVES OF 5-AMINOSALICYLIC ACID

By

SAMIRA YOUSEFI

May 2016

Chairman : Emilia bt Abd Malek, PhD
Faculty : Science

5-aminosalicylic acid (5-ASA), structurally related to the salicylates, is active in the treatment of inflammatory bowel disease (IBD). Since IBD is a high-incidence disease and considering that 5-ASA has been approved as one of the most effective and tolerable drug for the majority of patients in treatment of IBD, up to date, varied derivatives with slightly different formulation of 5-ASA have been prepared to allow it to reach different areas of the bowel and to help keep the condition in remission. On the other hand, according to the documentary evidences on the remarkable properties of fatty acids and saccharides in various areas especially in pharmaceutical field, they have been proposed as beneficial candidates for conjugating with drugs in order to enhance drugs' bioavailability. Therefore, in this work, a series of new monosaccharide selective ester derivatives of 5-ASA including galactose, fructose, glucose and xylitol esters and new fatty acid amide derivatives of 5-ASA including lauric, linoleic and oleic amide, were synthesized to study their anti-bacterial, anti-inflammatory and cytotoxicity activities in comparison with initial drug. The structures of all the produced compounds (sixteen compounds: including eleven unknown compounds and five known intermediates) were confirmed by spectroscopic methods (^1H NMR, ^{13}C NMR, IR and DIMS). Following that, the above-mentioned *in vitro* bioactivity evaluation was performed for all new final ester and amide derivatives of 5-ASA (four monosaccharide ester and three fatty acid amide derivatives). The antibacterial activity evaluation of them against Gram-negative bacteria and Gram-positive bacteria revealed that all were more effective against Gram-negative as well as Gram-positive bacteria than the parent drug (5-ASA) which showed insignificant activity. Furthermore, they were confirmed by the cytotoxicity assay over HT-29 and 3T3 cell lines to be less toxic for normal cells (3T3 cells) compared to the parent drug. On the other hand, however, their suppressive effect against colon cancerous cells (HT-29 cells) was somewhat lower. Meanwhile, the anti-inflammatory assay over RAW264.7 macrophage cell line demonstrated NO (nitric oxide) inhibition activity of these new derivatives of 5-ASA, moderately has improved in comparison with the parent drug. Although the mechanism of action of 5-ASA is still is unknown, but the clinical effectiveness of 5-ASA attributed to its inhibition effect on cyclooxygenase (COX-1/COX-2) and lipoxigenase (5-LOX) enzymes' pathways which are playing a vital role

in the inflammation process to produce inflammatory mediators. To predict the possible interactions and binding energy of the new compounds against these proteins, *in-silico* screening via molecular docking technique was performed and the new products exhibited greater hydrogen bonding and greater binding affinities with the active sites of proteins towards 5-ASA. As conclusion, eleven new monosaccharie ester and fatty acid amide derivatives of 5-ASA were synthesized successfully in average yields and showed approximately moderate to superior bioactivities for above-mentioned assays than 5-ASA which may help for drug development in future. Also, molecular docking was performed against two enzymes involved in the inflammation process to predict the possible interactions and binding energy of the new compounds for future *in-vivo* experimental works.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**SINTESIS, PENILAIAN BIOAKTIVITI SECARA IN-VITRO DAN DOK
MOLEKUL BAGI DERIVATIF ESTER MONOSAKARIDA DAN AMIDA ASID
LEMAK DARIPADA ASID 5-AMINOSALISILIK**

Oleh

SAMIRA YOUSEFI

Mei 2016

Pengerusi : Emilia bt Abd Malek, PhD
Fakulti : Sains

Asid 5-aminosalisilik (5-ASA), berkait rapat secara struktur dengan salisilat, yang aktif dalam penyakit keradangan usus (IBD). Disebabkan IBD adalah penyakit yang paling kerap berlaku dan memandangkan 5-ASA telah diluluskan sebagai ubat yang paling berkesan dan boleh diterima bagi majoriti pesakit dalam rawatan IBD, sehingga kini, pelbagai derivatif dengan sedikit perubahan terhadap 5-ASA telah disediakan untuk membolehkan ia untuk sampai ke kawasan yang berbeza-beza dalam usus dan membantu dalam penyembuhan. Selain daripada itu, sesuai dengan bukti-bukti dokumentari mengenai sifat-sifat mengagumkan daripada asid lemak dan sakarida dalam pelbagai bidang terutama dalam bidang farmaseutikal, mereka telah dicadangkan sebagai calon bermanfaat untuk dicantumkan dengan ubat-ubatan untuk meningkatkan kadar serapan dadah ke dalam tisu badan. Satu siri ester selektif terhadap monosakarida 5-ASA termasuk ester galaktosa, fruktosa, glukosa dan xilitol, dan asid lemak amida terbitan 5-ASA termasuk amida laurik, linoleik dan oleik yang baru telah disintesis bagi mengkaji aktiviti anti-mikrob, anti-kanser dan anti-radang mereka berbanding dengan ubat asal. Struktur bagi semua sebatian yang dihasilkan (enam belas sebatian termasuk sebelas sebatian tidak diketahui dan lima sebatian diketahui) telah disahkan menggunakan kaedah spektroskopi (^1H NMR, ^{13}C NMR, IR and DIMS). Berikutan itu, penilaian bioaktiviti *in vitro* seperti yang telah disebutkan telah dijalankan ke atas kesemua derivatif ester dan amida 5-ASA (empat derivative ester monosakarida dan tiga derivatif amida asid lemak.) Aktiviti antibakteria bagi produk baru ini telah diuji terhadap bakteria Gram-negatif dan bakteria Gram-positif. Keputusan penilaian aktiviti anti-bakteria mendapati kesemua sebatian baru lebih berkesan terhadap Gram-negatif dan juga bakteria Gram-positif berbanding sebatian asal (5-ASA) yang menunjukkan aktiviti yang tidak ketara. Tambahan pula, mereka telah disahkan melalui penilaian sitotoksik terhadap bahagian sel HT-29 dan 3T3 sebagai kurang toksik terhadap sel normal (sel 3T3) berbanding sebatian asal. Walaubagaimanapun, kesan sekatan terhadap sel kanser kolon (sel HT-29) adalah lebih rendah. Sementara itu, penilaian anti-radang bagi semua

produk baru terhadap sel makrofaj RAW264.7 telah menunjukkan peningkatan sederhana bagi perencatan aktiviti nitrik oksida (NO) berbanding sebatian induk. Walaupun mekanisme tindakan 5-ASA masih tidak diketahui, tetapi keberkesanan klinikal 5-ASA dikaitkan dengan kesan perencatan pada siklooksigenase (COX -1 / COX- 2) dan laluan lipooksigenase (5- LOX) enzim yang memainkan peranan penting dalam proses keradangan untuk menghasilkan pengantara keradangan. Untuk meramalkan interaksi mungkin dan tenaga pengikat sebatian baru terhadap protein ini saringan *in-silico* melalui teknik dok molekul telah dilakukan dan produk baru mempamerkan ikatan hidrogen dan affiniti pengikatan yang lebih besar terhadap tapak aktif protein berbanding 5-ASA. Kesimpulannya, sebelas derivatif ester monosakarida dan asid lemak amida 5-ASA yang baru telah berjaya disintesis dengan hasil purata dan menunjukkan bioaktiviti yang sederhana atau lebih baik bagi bioesei yang telah disebutkan berbanding 5-ASA yang boleh membantu pembangunan ubat-ubatan masa hadapan. Di samping itu, dok molekul telah dilakukan terhadap dua enzim yang terlibat dalam proses keradangan bagi meramalkan interaksi mungkin dan tenaga pengikatan sebatian baru untuk kerja-kerja eksperimental *in vivo* masa hadapan.

ACKNOWLEDGEMENTS

First and foremost, praise is to “The Almighty God” sustainer of the world for blessing me and giving me strengths, health and determination to complete this thesis. I would like to express my sincere and deepest gratitude to my supervisor, Dr. Emilia Abd Malek who has not just been an excellent supervisor, she has been a mentor, a pillar of support and a good friend to me. Her encouraging words in all the times were the best. I could not imagine completing this work without her help and it has been a huge pleasure to do my Ph.D program under her supervision.

Many thanks to my supervisory committee: Prof. Dr. Mohd Basyaruddin Abdul Rahman and Prof. Madya Dr. Intan Safinar Ismail for the continuous support of my Ph.D study and research, for their encouragement and insightful comments.

Sincere thanks are extended to my friend Dr. Saadi Bayat because of his knowledge and deep concern during the research program.

I am grateful of Elnaz Saki, Sze Wei Leong, Majid Froghi and Zalikha Ibrahim for their kind cooperation in this research.

My appreciation also goes to Dr. Hamidreza Fard Masoomi and all my fellow labmates in laboratories 401, 105 and chemistry department: Shazwani, Fazriana, Rizanna, Lim, Azhar, Mahashanon, Zahra, Sharil, Hiba and all students in our groups for their friendship that never fails to help and for all the fun we have had in the last three years.

I am grateful to NMR, FT-IR, GC-MS persons in charge for their friendly collaboration to analyze my compounds in Faculty of Science Universiti Putra Malaysia and Malaysian Genome Intitute (MGI). Moreover, I wish to thank Mrs. Nor Aini in Institute of Bioscience (IBS) for her cooperation in this research.

I would also like to convey thanks to the Ministry of Higher Education of Malaysia and Faculty of Science Universiti Putra Malaysia for providing the financial means and laboratory facilities.

I am very thankful of Alireza Safian for being a constant source of motivation and for his kind help in computer skills for this dissertation.

Last but not the least, I wish to express my love and gratitude to my beloved family; for their understanding & endless love, through the duration of my study.

I certify that a Thesis Examination Committee has met on 18 May 2016 to conduct the final examination of Samira Yousefi on her thesis entitled "Synthesis, In-Vitro Bioactivity Evaluation and Molecular Docking of Monosaccharide Ester and Fatty Acid Amide Derivatives of 5-Aminosalicylic Acid" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Mohamed Ibrahim bin Mohamed Tahir, PhD

Senior Lecturer
Faculty of Science
Universiti Putra Malaysia
(Chairman)

Gwendoline Ee Cheng Lian, PhD


Professor
Faculty of Science
Universiti Putra Malaysia
(Internal Examiner)

Khozirah binti Shaari, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Internal Examiner)

Allan D. Headley, PhD

Professor
Texas A & M University-Commerce
United States
(External Examiner)



ZULKARNAIN ZAINAL, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 26 July 2016

This thesis submitted to the Senate of Universiti Putra Malaysia has been accepted as fulfillment of the requirements for the degree of Doctor of Philosophy. The members of the Supervisory committee were as follows:

Emilia Abd Malek, PhD

Senior lecturer
Faculty of Science
Universiti Putra Malaysia
(Chairman)

Mohd Basyaruddin Abd Rahman, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

Intan Safinar Ismail, PhD

Associate Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by Graduate Student

I hereby confirm that:

- This thesis is my original work;
- Quotations, illustrations and citations have been duly referenced;
- This thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- Intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- Written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- There is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____ Date: _____

Name and Matric No : Samira Yousefi, (GS36651)

Declaration by Members of Supervisory Committee

This is to confirm that:

- The research conducted and the writing of this thesis was under our supervision;
- Supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of Chairman of Supervisory Committee: Emilia Abd Malek, PhD

Signature: _____

Name of Member of Supervisory Committee: Mohd Basyaruddin Abd Rahman, PhD

Signature: _____

Name of Member of Supervisory Committee: Intan Safinar Ismail, PhD

TABLE OF CONTENTS

	Page
ABSTARACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xiii
LIST OF FIGURES	xv
LIST OF ABRREVIATIONS	xix
CHAPTER	
1. INTRODUCTION	1
1.1 Problem Statements	2
1.2 Goals and objectives of the study	3
2. LITERATURE REVIEW	4
2.1 5-Aminosalicylic acid	4
2.1.1 Azo-bond derivatives of 5-ASA	5
2.1.2 Non-azo-bond derivatives of 5-ASA	6
2.1.3 Mechanism of action of 5-ASA	8
2.2 Saccharides	11
2.3 Fatty acids	17
2.4 Computer-assisted drug design for drug development and design	19
2.4.1 Molecular docking	19
2.5 Synthesis methods for ester and amide bonds formation	22
2.6 Protecting hydroxyl group of sugars	26
3. MATERIALS AND METHOD	28
3.1 Materials	28
3.2 Method	28
3.2.1 General procedure for preparing 5-aminosalicylic acid monosaccharide selective esters	30
3.2.2 Preparation of 5-ASA fatty acid amide derivatives	37
3.3 Product Analysis	38
3.3.1 Thin layer Chromatography (TLC)	38
3.3.2 Nuclear Magnetic Resonance Spectroscopy (NMR)	38
3.3.3 Fourier-Transform Infrared Spectroscopy (FT-IR)	38
3.3.4 Mass Spectrometry (MS)	38
3.3.5 Optical rotation for diacetone-monosaccharide	39
3.4 Characterization of synthesized compounds	39
3.4.1 <i>N</i> -acetyl-5-aminosalicylate or 5-acetamido-2-hydroxy benzoic acid	40

3.4.2	1,2:3,4-di- <i>O</i> -isopropylidene-D-galactopyranose or diacetone-galactose	41
3.4.3	2,3:4,5-di- <i>O</i> -isopropylidene-D-fructopyranose or diacetone-fructose	42
3.4.4	1,2:5,6-di- <i>O</i> -isopropylidene-D-glucofuranose or diacetone-glucose	43
3.4.5	2,3:4,5-di- <i>O</i> -isopropylidene-D-xylitol or diacetone-xylitol	44
3.4.6	6- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-1,2:3,4-di- <i>O</i> -isopropylidene-D-galactopyranose	45
3.4.7	1- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-2,3:4,5-di- <i>O</i> -isopropylidene-D-fructopyranose	46
3.4.8	3- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-1,2:5,6-di- <i>O</i> -isopropylidene-D-glucofuranose	47
3.4.9	1- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-2,3:4,5-di- <i>O</i> -isopropylidene-D-xylitol	48
3.4.1	6- <i>O</i> -5-aminosalicylate-D-galactopyranose	49
3.4.1	1- <i>O</i> -5-aminosalicylate-D-fructopyranose	50
3.4.1	3- <i>O</i> -5-aminosalicylate-D-glucopyranose	51
3.4.1	1- <i>O</i> -5-aminosalicylate-D-xylitol	52
3.4.1	5-ASA lauric amide	53
3.4.1	5-ASA linoleic amide	54
3.4.1	5-ASA oleic amide	55
3.5	Anti-bacterial assay over Gram-negative and Gram-positive bacteria	56
3.6	Anti-inflammatory assay against nitric oxide	56
3.6.1	Cell culture	56
3.6.2	Nitrite determination	57
3.6.3	MTT assay over macrophage cell line	57
3.7	Cytotoxicity assay over normal cells (3T3 cells) and colon cells (HT-29)	57
3.7.1	Preparation of test compounds	57
3.7.2	Procedure of MTT assay	58
3.8	Docking study	60
3.8.1	Preparation of proteins and ligands	60
3.8.2	Preparation of Grid box	60
3.8.3	Preparing AutoDock	60
4.	RESULTS AND DISCUSSTIONS	61
4.1	Synthesis	61
4.1.1	Synthesis of monosaccharide ester derivatives of 5-ASA	61
4.1.2	Synthesis of fatty acid amide derivatives of 5-ASA	75
4.2	Anti-bacterial evaluation	81
4.2.1	Anti-bacterial evaluation of 5-ASA monosaccharide	81
4.2.2	Anti-bacterial evaluation of 5-ASA fatty acid amides	82

4.3	Anti-inflammatory evaluation	85
4.3.1	Anti-inflammatory evaluation of 5-ASA monosaccharide esters	85
4.3.2	Anti-inflammatory evaluation of 5-ASA fatty acid amides	85
4.4	Cytotoxicity evaluation	87
4.4.1	Cytotoxicity evaluation of 5-ASA monosaccharide esters	87
4.4.2	Cytotoxicity evaluation of 5-ASA fatty acid amides	89
4.5	Molecular docking analysis	92
4.5.1	Molecular docking study with COX-1 protein	92
4.5.2	Molecular docking study with COX-2 protein	96
4.5.3	Molecular docking study with 5-LOX protein	99
5.	CONCLUSION AND RECOMMENDATIONS	103
5.1	Conclusion	103
	REFERENCES	105
	APPENDICES	118
	BIODATA OF STUDENT	213
	LIST OF PUBLICATIONS	214

LIST OF TABLES

Table	Page	
3.1	Mass Spectrometry Parameters for DIMS	39
4.1	Important IR frequencies of major functional groups in the IR spectra of diacetone monosaccharides.	65
4.2	Important protons in the ^1H NMR spectra of diacetone monosaccharides.	66
4.3	Important carbon chemical shifts in the ^{13}C NMR spectra of diacetone monosaccharides.	66
4.4	Important IR frequencies of major functional groups in the IR spectra of <i>N</i> -acetyl-5-aminosalicylate diacetone monosaccharides.	68
4.5	Important protons in the ^1H NMR spectra of <i>N</i> -acetyl-5-aminosalicylate diacetone monosaccharides.	69
4.6	Important carbon chemical shifts in the ^{13}C NMR spectra of <i>N</i> -acetyl-5-aminosalicylate diacetone monosaccharides.	70
4.7	Important IR frequencies of major functional groups in the IR spectra of 5-ASA monosaccharide esters.	72
4.8	Important protons in the ^1H NMR spectra of 5-ASA monosaccharide esters.	73
4.9	Important carbon chemical shifts in the ^{13}C NMR spectra of 5-ASA monosaccharide esters.	73
4.10	Important IR frequencies of major functional groups in the IR spectra of 5-ASA fatty acid amide derivatives.	76
4.11	Important protons in the ^1H NMR spectra of 5-ASA fatty acid amide.	77
4.12	Important carbon chemical shifts in the ^{13}C NMR spectra of 5-ASA fatty acid amide derivatives.	78
4.13	In vitro antibacterial activity evaluation of monosaccharide derivatives of 5-ASA via disk diffusion assay against both Gram-positive and Gram-negative bacteria, the test was duplicated and the averages inhibition zone were recorded.	82
4.14	In vitro antibacterial activity evaluation of fatty acid derivatives of 5-ASA via disk diffusion assay against both Gram-positive and Gram-negative bacteria, the test was duplicated and the averages inhibition zone were recorded.	83
4.15	In vitro anti-inflammatory evaluation of 5-ASA monosaccharide esters via nitric oxide (NO) inhibition assay with cytotoxicity test on RAW 264.7 cells at 50 μM of test compounds.	85
4.16	In vitro anti-inflammatory evaluation of 5-ASA fatty acid amides via nitric oxide (NO) inhibition assay with cytotoxicity test on RAW 264.7 cells at 50 μM of test compounds.	86
4.17	In vitro cytotoxicity evaluation of 5-ASA monosaccharide derivatives via MTT assay against colon cancer cells (HT-29) and normal cells (3T3 cell lines).	87

4.18	In vitro cytotoxicity evaluation of 5-ASA fatty acid derivatives via MTT assay against colon cancer cells (HT-29) and normal cells (3T3 cell lines).	89
4.19	The docking results (AutoDock 4.2) of parent drug, co-crystal ligand and monosaccharide derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in COX-1 with their distances or lengths of hydrogen bonds: [D (Å)].	94
4.20	The docking results (AutoDock 4.2) of fatty acid derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in COX-1 with their distances or lengths of hydrogen bonds: [D (Å)].	95
4.21	The docking results (AutoDock 4.2) of parent drug, co-crystal ligand and monosaccharide derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in COX-2 with their distances or lengths of hydrogen bonds: [D (Å)].	97
4.22	The docking results (AutoDock 4.2) of fatty acid derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in COX-2 with their distances or lengths of hydrogen bonds: [D (Å)].	98
4.23	The docking results (AutoDock 4.2) of parent drug and monosaccharide derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in 5-LOX with their distances or lengths of hydrogen bonds: [D (Å)].	100
4.24	The docking results (AutoDock 4.2) of fatty acid derivatives of 5-ASA, regarding the binding free energy: [ΔG (kcal/mol)] and hydrogen bonds between compounds and amino acids involved in 5-LOX with their distances or lengths of hydrogen bonds: [D (Å)].	101

LIST OF FIGURES

Figure	Page
1.1 Structure of 5-ASA.	1
2.1 Structure of some azo derivatives of 5-ASA, (Carceller et al., 2001).	5
2.2 Biodegradable azo-containing polyurethanes of 5-ASA, (Davaran et al., 2006).	6
2.3 Splitting of HPAS at the azo bond by the colonic bacteria to release 5-ASA in the colon, (Mahkam et al., 2006).	6
2.4 Structure of some amino acid derivatives of 5-ASA (1: Clerici et al., 1994, 2-3-4: Jung et al., 2001).	7
2.5 5-ASA ester (5) and amide (6) derivatives with dextran (5: Jung et al., 1998, Ahmad et al., 2006).	8
2.6 Me5-ASA was bonded to PCL (polycaprolactone) to prepare the NP formulation of 5-ASA through Oil/water emulsification methods (Pertuit et al., 2007).	8
2.7 Diagram of major pathways involved in converting arachidonic acid to inflammation intermediates which is catalyzed by COXs and LOX enzymes. The pharmacological activity of NSAIDs and ASA drugs is attributed to the suppression of inflammation mediators by inhibiting catalytic action of COXs and LOX enzymes. PLA2: phospholipase A2, PG: prostaglandin, TX: thromboxane, LT: leukotriene.	10
2.8 Structure of glycosides of hydroxyurea (7) and glycosides of mesylglycol (8), (Sorg et al., 2005).	11
2.9 Structure of ibuprofen-fructose (Mahmmod, 2008).	12
2.10 Structure of porphyrin-saccharide (Cai et al., 2003).	13
2.11 Glucose-aspirin (Jacob and Tazawa, 2012).	13
2.12 Structure of ibuprofen glucose ester (9), gentisic acid glucose ester(10), galic acid glucose ester (11) and α -tocopherol glucose ester (12), (Uhrig et al., 2000).	14
2.13 Structure of perfluoroalkylated sugars, (Paleta et al., 2002).	15
2.14 Some butyric and fatty acid derivatives of xylitol (Rufino et al., 2009, Pouillart et al., 1999).	16
2.15 Structure of xylitol esters with caproic acid and capric acid (n = 4 and n = 8, respectively), (Adnani et al., 2011a).	17
2.16 Showing diclofenac docked in its best conformation into the binding site of 1PXX protein forming one hydrogen bond with Ser530 and one hydrogen bond with Tyr385, (Palkar et al., 2014).	20
2.17 Spatial orientation and superimposition of 12a molecule (an active analogue of celecoxib shown in yellow colour) over S58 crystal ligand within 3.5 Å° active site residues, (Adinarayana et al., 2012).	21
2.18 Preparation of monomeric derivative of 5-ASA with HEMA catalyzed by SOCl ₂ , (Rajesh, 2011).	22
2.19 Protection of carboxylic acid group of 5-ASA with methanol catalyzed by SOCl ₂ , (Pertuit et al., 2007).	23

2.20	Transesterification between methyl salicylate with sorbitol via enzymatic synthesis, (Maugard et al., 2001).	24
2.21	Synthesis of glucose aspirin using DCC and DMAP as catalysts.	25
2.22	Synthesis of Me5ASA-PCL by coupling reagents in presence of protic additives, (Pertuit et al., 2007).	25
2.23	Selective protection of hydroxyl groups of glucose for preparing its 6-O derivatives, (Lu et al., 2005).	27
2.24	Selective protection of hydroxyl groups of glucose for preparing its 3-O derivatives, (Abeylath, 2007).	27
2.25	Protection of xylitol in presence of acetone and an organic acid.	27
3.1	Flow diagram of the experimental work.	29
3.2	Preparation of <i>N</i> -acetyl-5-aminosalicylate.	31
3.3	Preparation of 1,2:3,4-Di- <i>O</i> -isopropylidene- <i>D</i> -galactopyranose (diacetone galactose) 1,2:4,5-Di- <i>O</i> -isopropylidene- <i>D</i> -fructopyranose (diacetone fructose) 1,2:5,6-Di- <i>O</i> -isopropylidene- <i>D</i> -glucofuranose (diacetone glucose) and/or 2,3:4,5-Di- <i>O</i> -isopropylidene- <i>D</i> -xylitol (diacetone xylitol).	32
3.4	Preparation of <i>N</i> -acetyl-5-aminosalicylate diacetone-monosaccharide ester derivatives.	34
3.5	Preparation of <i>O</i> -5-aminosalicylate monosaccharide esters.	36
3.6	Preparation of 5-ASA fatty acid amide derivatives.	37
3.7	<i>N</i> -acetyl-5-aminosalicylate.	40
3.8	1,2:3,4-di- <i>O</i> -isopropylidene- <i>D</i> -galactopyranose.	41
3.9	2,3:4,5-di- <i>O</i> -isopropylidene- <i>D</i> -fructopyranose.	42
3.10	1,2:5,6-di- <i>O</i> -isopropylidene- <i>D</i> -glucofuranose.	43
3.11	2,3:4,5-di- <i>O</i> -isopropylidene- <i>D</i> -xylitol.	44
3.12	6- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-1,2:3,4-di- <i>O</i> -isopropylidene- <i>D</i> -galactopyranose.	45
3.13	1- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-2,3:4,5-di- <i>O</i> -isopropylidene- <i>D</i> -fructopyranose.	46
3.14	3- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-1,2:5,6-di- <i>O</i> -isopropylidene- <i>D</i> -glucofuranose.	47
3.15	1- <i>O</i> - <i>N</i> -acetyl-5-aminosalicylate-2,3:4,5-di- <i>O</i> -isopropylidene- <i>D</i> -xylitol.	48
3.16	6- <i>O</i> -5-aminosalicylate- <i>D</i> -galactopyranose.	49
3.17	1- <i>O</i> -5-aminosalicylate- <i>D</i> -fructopyranose.	50
3.18	3- <i>O</i> -5-aminosalicylate- <i>D</i> -glucofuranose.	51
3.19	1- <i>O</i> -5-aminosalicylate- <i>D</i> -xylitol.	52
3.20	5-ASA lauric amide.	53
3.21	5-ASA linoleic amide.	54
3.22	5-ASA oleic amide.	55

3.23	A schematic of a 96 well microplate in proliferation assay against HT-29 cells. In each well equal amount of MTT were added to previously grown cells. However, the concentrations of test compounds from 0 to 100 µg/mL were differed in each row of A to H rows, respectively. In higher concentrations of compounds, cell viability and as a result intensity of purple formazan was decreased. MTT assay was done in triplicate for each test compounds and the average optimal density was recorded at 570 nm. (Intensive purple colour records higher absorbance).	59
3.24	Reduction of Yellow MTT to purple formazan by mitochondrial enzymes.	59
4.1	Proposed mechanism for preparing N-acetyl 5-aminosalicylate.	62
4.2	Proposed mechanism for preparing diacetone monosaccharides catalyzing by ZnCl ₂ and/or a mineral acid (HX).	64
4.3	Proposed mechanism for deprotection of N-acetyl-5-aminosalicylate diacetone monosaccharides to prepare 5-ASA monosaccharide esters.	71
4.4	Reagents and conditions: (i) H ₃ PO ₄ , 80C° ; (ii) acetone, ZnCl ₂ , H ₃ PO ₄ , 5 h ; (iii) DMAP, DCM, DCC, 24 h, r.t ; (iv) acetic acid 85%, reflux under N ₂ gas, 5 h. (13): N-acetyl-5-aminosalicylate, 67.5%. (14): Diacetone galactose, 63.8%. (15): Diacetone fructose, 58.3%. (16): Diacetone glucose, 61%. (17): Diacetone xylitol, 57%. (18) 6- <i>O</i> -N-acetyl-5-aminosalicylate-1,2:3,4-Di- <i>O</i> -isopropylidene-D-galactopyranose, 51%. (19): 1- <i>O</i> -N-acetyl-5-aminosalicylate-2,3:4,5-Di- <i>O</i> -isopropylidene-D-fructopyranose, 48%. (20): 3- <i>O</i> -N-acetyl-5-aminosalicylate-1,2:5,6-Di- <i>O</i> -isopropylidene-D-glucofuranose, 57%. (21), 1- <i>O</i> -N-acetyl-5-aminosalicylate-2,3:4,5-Di- <i>O</i> -isopropylidene-D-xylitol, 47%. (22): 6- <i>O</i> -5-aminosalicylate-D-galactopyranose, 31%. (23): 1- <i>O</i> -aminosalicylate-D-fructopyranose, 35%. (24): 3- <i>O</i> -5-aminosalicylate-D-glucofuranose, 41%. (25): 1- <i>O</i> -5-aminosalicylate-D-xylitol, 38%.	74
4.5	Synthesis of fatty acid derivatives of 5-ASA	75
4.6	Proposed mechanism for preparation of 5-ASA ester and amide derivatives using DCC/DMAP coupling reagents.	80
4.7	Images of petri plates in anti-bacterial test via disk diffusion method against (A): Staphylococcus aureus and (B) Escherichia coli bacteria for monosaccharide derivatives of 5-ASA. No. 1: 5-ASA galactose ester, No. 2: 5-ASA fructose ester, No. 3: 5-ASA glucose ester, No. 4: 5-ASA xylitol ester, No. 5: 5-ASA, No 6: negative control (ethanol), No. 7: positive control (streptomycin).	81
4.8	Images of petri plates in anti-bacterial test via disk diffusion method against (A): Staphylococcus aureus and (B) Escherichia coli bacteria for fatty acid derivatives of 5-ASA. No. 1: 5-ASA oleic amide, No. 2: 5-ASA linoleic amide, No. 3: 5-ASA lauric amide, No. 4: 5-ASA, No. 5: positive control (streptomycin), No. 6: negative control (ethanol).	83
4.9	Diagrams of cytotoxicity assays depicted base on cell viability (%) to concentration of monosaccharide derivatives of 5-ASA against 3T3 and HT-29 cell lines.	88

- 4.10 Diagrams of cytotoxicity assays depicted base on cell viability (%) to concentration of fatty acid derivatives of 5-ASA against 3T3 and HT-29 cell lines.

90



LIST OF ABBREVIATIONS

Δ	Chemical Shift
ΔG	Gibbes Energy
5-ASA	5-Amino salicylic acid
5-LOX	5-Lipoxygenase
ASA	Amino salicylic acid
<i>c</i> / conc.	Concentration / Concentrated
CADD	Computer-Assisted Drug Design
Calcd	Calculated
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
DCC	Dicyclohexylcarbodiimide
DCM	Dichloromethane
DIMS	Direct Infusion Mass Spectrometry
DMAP	Dimethylaminopyridine
DMSO	Dimethyl Sulfoxide
DHU or DCU	Dicyclohexyl urea
eq / equiv.	Equivalents
ESI	Electrospray Ionisation
Et ₃ N	Triethylamine
FDA	Food and Drug Administration
FT	Fourier Transformation
GC	Gas Chromatography
H	Hours
HOBT	Hydroxybenzotriazole
HOSU	<i>N</i> -hydroxysuccinimide
IBD	Inflammatory Bowel Disease
IR	Infrared (Spectroscopy)
<i>J</i>	NMR Coupling Constant
LT	Leukotriene
M	Molar
Min	Minutes
M.p	Melting Point
<i>m/z</i>	Mass to Charge Ratio
MS	Mass Spectroscopy
NMM	<i>N</i> -methylmorpholine
NA	Nutrient agar
NMR	Nuclear Magnetic Resonance
NSAID	Nonsteroidal Anti-inflammatory Drug
<i>p</i>	Para
PG	Prostaglandin
Ph	Phenyl
PLA ₂	Phospholipase A2
QSAR	Quantitative Structure Activity Relationship
RMSD	Root-mean square deviation
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SD	Standard Deviation
S.E.M	Standard Error of the Mean
SP	Sulfapyridine

TLC
TMS
TX

Thin Layer Chromatography
Tetramethylsilane
Thromboxane



CHAPTER 1

INTRODUCTION

Inflammatory bowel disease (IBD) is a high-incidence disease which is induced by a complex interplay among environmental, genetic and immunoregulatory factors (Hanauer, 2006, Giannini *et al.*, 2005). Also, IBD is a main risk factor for developing colorectal cancer which covers a wide range of patients' ages, (Friend, 2005, Giannini *et al.*, 2005, Tursi *et al.*, 2011). If IBD not treated properly, it can lead to outbreak of two major colon associated diseases, namely ulcerative colitis and Crohn's disease, (Yang *et al.*, 2014, Williams *et al.*, 2011, Giannini *et al.*, 2005, Friend, 2005). Therefore, high priority should be accorded to the achievement of better therapeutic effects for the treatment of IBD.

5-Aminosalicylic acid (5-ASA), (Figure 1.1) has been the most widely prescribed anti-inflammatory drug for recovering and maintaining the relapse of IBD due to its limited side effects and its tolerability for the majority of patients (Giannini *et al.*, 2005, Stolfi *et al.*, 2008, Tursi *et al.*, 2011). 5-ASA was approved by FDA (food and drug administration) in 1987 (Williams *et al.*, 2011, Couto *et al.*, 2010, Ahmad *et al.*, 2006) and in the market is known with different commercial brands such as mesalamine, mesalazine and asacol,. Both experimental and epidemiological studies have revealed that in long-term usage, 5-ASA represses gastrointestinal toxicity (Friend, 2005) and acts as a chemopreventive agent (Lopez *et al.*, 2012, Ahmad *et al.*, 2006, Ritland *et al.*, 1999) particularly against colitis-associated cancers (Campregher *et al.*, 2010).

5-ASA has been introduced as an antioxidant agent as well, since its scavenging effects has been verified against reactive oxygen and nitrogen species (ROS and RNS, respectively), (Couto *et al.*, 2010).




Figure 1.1 Structure of 5-ASA.

Unfortunately, to date, the exact mechanism of action and metabolism of 5-ASA has not entirely found yet, but it presumes that 5-ASA reduces inflammation by inhibiting cyclooxygenase and lipoxygenase enzymes' pathways which catalyze the production of prostaglandins and other inflammatory mediators in the intestine (Carmine *et al.*, 2008, Shiff 2003).

On the other hand, sugar drug derivatives have opened a new gateway in medicine and pharmaceutical fields and recently, a great number of drugs in use have relied on carbohydrates (Quan *et al.*, 2007b). It has been found that incorporation of carbohydrates with drugs improves permeation of the drugs into the cell membranes and increases delivery of drugs to the targeted site (Quan *et al.*, 2007b). Also it has been reported that glycosidic linkage, raises the water-solubility and stability of biocompatibility of drugs (Kohane *et al.*, 2002). Glycotargeting also has demonstrated that carbohydrate ligands can feasibly interact to target protein receptors at the sites of localization (Kuehl *et al.*, 2005). Not only the antimicrobial (Douglas L. Marshall *et al.*, 1994) and anti-tumor (Okabe *et al.*, 1999) properties of carbohydrates but also their anti-inflammatory characteristics in some synthetic compounds possessing glycosidic linkages (Soni *et al.*, 2014) have been proven thus, offering them a potential choice for conjugation to drugs in order to improve their biological activities.

Fatty acids (either saturated or unsaturated carboxylic acids with variable aliphatic chain lengths), are known for their health benefits (Williams, 2000, Field *et al.*, 2009) in cosmetic, pharmaceutical, and food industries (Adnani *et al.*, 2011a, Zhu *et al.*, 1989). They are mostly available in natural resources such as animal, vegetable fats and oils (Yang *et al.*, 2012, Adamopoulos, 2006). In medicine, fatty acid derivatives have wide applications due to their anti-obesitic, anti-carcinogenic, anti-atherogenic, anti-diabetogenic, immunomodulatory, apoptotic and osteosynthetic effects (Benjamin *et al.*, 2009). Fatty acids have exhibited activity in improving antibacterial properties of their derivatives (Adnani *et al.*, 2011a, Waterman *et al.*, 2007). Intracellular absorption of some derivatives of fatty acid are raised in the related tract because of fatty acids' amphipathic property (Fitscher *et al.*, 1996). Also, the mediation of fatty acid's moiety in enhancing anti-inflammatory and anti-tumour activities of some drug derivatives has introduced them as multivalent compounds.

1.1 Problem Statements

Despite the remarkable advantages of 5-ASA and producing its derivatives in order to improve therapeutic properties of this drug, patient life quality has so far not been improved. This is due to the fact that, when the drug is taken orally or used in the form of a suppository, the main portion of the drug is absorbed in the small intestine and hardly reaches the colon (Giannini *et al.*, 2005). Its low stability in the gastrointestinal tract (Abdu-Allah *et al.*, 2005) and poor water solubility (Aguzzi *et al.*, 2011, Aguzzi *et al.*, 2010, Zou *et al.*, 2005) are other problems which result in the necessary consumption of a higher dosage of the drug in order to be effective, the requirement of long-term treatment and a greater number of side effects. Also, in some cases, the disease relapses and surgery is required (Friend, 1991, Freeman, 2012, Williams *et al.*, 2011).

As regards, conjugation of drugs with saccharides and fatty acids offers a lot of opportunities to enrich bioavailability and pharmaceuticals properties, (Uhrig *et al.*, 2000, Jacob *et al.*, 2012, Chen *et al.*, 2004) in this current work, both monosaccharide ester derivatives and fatty acid amide derivatives of 5-ASA were synthesized to study some biological activities of this drug including antibacterial, anti-inflammatory and cytotoxicity activities in comparison with the parent drug.

In addition, preparation of 5-ASA's ester and amide derivatives was suggested because it has been found that ester bond is fairly fixed in the acidic medium and readily ruptured in the basic environment which is compatible with gut nature (Rajesh, 2011) and may enable the drug glycoside to release the active drug in the colonic tract through enzymatic action. It has also been reported that the amide bond is stable in the upper part of the intestine, and as a result a large quantity of the orally administered prodrug might be delivered to the colon where it will be degraded by amidases of microflora to release the drug (Abdu-Allah *et al.*, 2005).

Time and resources consuming processes are major problems in drug discovery and development. Computer-based analysis is utilized as a key tool in the field of molecular modelling to expedite and facilitate drug discovery and development processes. One of the useful computational techniques for exploring the interactions and binding energy of ligands into receptors is structure (target)-based design or molecular docking, (Charlier *et al.*, 2003, Palkar *et al.*, 2014, Hegazy *et al.*, 2012, Kapetanovic, 2008). Since cyclooxygenase and lipoxygenase proteins have been introduced to be effective in inflammation process, the behaviour of new compounds on COX-1, COX-2 and 5-LOX proteins was screened via *in silico* molecular docking and was compared with the original drug.

1.2 Goals and objectives of the study

Considering that to date there are no published reports on synthesis of monosaccharide and fatty acid derivatives of 5-ASA, hence, the objectives were set as follows:

- 1) To synthesize and characterize monosaccharide ester and fatty acid amide derivatives of 5-ASA.
- 2) To evaluate the *in-vitro* bioactivities of the new compounds including antibacterial, anti-inflammatory and cytotoxicity activities in comparison with 5-ASA.
- 3) To predict specifications of the new compounds onto effective enzymes in producing inflammatory mediators including COX-1, COX-2 and 5-LOX proteins via *in-silico* molecular docking in order to obtain further leads for drug design and discovery developments in future studies or experimental works.

REFERENCES

- Abdu-Allah, H., Abdel-Alim, A., Abdel-Moty, S. & El-Shorbagi, A. (2005). Synthesis of trigonelline and nicotinamide linked prodrugs of 5-aminosalicylic acid (5-ASA) with analgesic and anti-inflammatory effects. *Bulletin of pharmaceutical sciences-assiut university* 28 (2), 237.
- Abdulmalek, E., Saupi, H. S. M., Tejo, B. A., Basri, M., Salleh, A. B., Rahman, R. N. Z. R. A. & Rahman, M. B. A. (2012). Improved enzymatic galactose oleate ester synthesis in ionic liquids. *Journal of Molecular Catalysis B: Enzymatic*, 76 (37-43).
- Abeylath, T. W. S. C. (2007). Glyconanobiotics: Novel carbohydrate nanoparticle polymers.
- Adamopoulos, L. 2006. *Understanding the formation of sugar fatty acid esters*. Master Thesis, North Carolina State University.
- Adinarayana, K., Reddy, P. A. & Babu, P. A. (2012). Structural studies on docking selective COX-2 inhibitors. *J. of Bioinformatics & Research*, 1 (1), 21-26.
- Adnani, A., Basri, M., Chaibakhsh, N., Ahangar, H. A., Salleh, A. B., Rahman, R. N. Z. R. A. & Rahman, M. B. A. (2011a). Chemometric analysis of lipase-catalyzed synthesis of xylitol esters in a solvent-free system. *Carbohydrate Research*, 346 (4), 472-479.
- Adnani, A., Basri, M., Chaibakhsh, N., Rahman, M. B. A. & Salleh, A. B. (2011b). Artificial neural network analysis of lipase-catalyzed synthesis of sugar alcohol ester. *Industrial Crops and Products*, 33 (1), 42-48.
- Adnani, A., Basri, M., Malek, E. A., Salleh, A. B., Rahman, M. B. A., Chaibakhsh, N. & Rahman, R. N. Z. R. A. (2010). Optimization of lipase-catalyzed synthesis of xylitol ester by Taguchi robust design method. *Industrial Crops and Products*, 31 (2), 350-356.
- Aguzzi, C., Capra, P., Bonferoni, C., Cerezo, P., Salcedo, I., Sánchez, R., Caramella, C. & Viseras, C. (2010). Chitosan-silicate biocomposites to be used in modified drug release of 5-aminosalicylic acid (5-ASA). *Applied Clay Science*, 50 (1), 106-111.
- Aguzzi, C., Ortega, A., Bonferoni, M., Sandri, G., Cerezo, P., Salcedo, I., Sánchez, R., Viseras, C. & Caramella, C. (2011). Assessment of anti-inflammatory properties of microspheres prepared with chitosan and 5-amino salicylic acid over inflamed Caco-2 cells. *Carbohydrate polymers*, 85 (3), 638-644.
- Ahmad, S., Tester, R. F., Corbett, A. & Karkalas, J. (2006). Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. *Carbohydrate research*, 341 (16), 2694-2701.

- Babazadeh, M., Edjlali, L. & Rashidian, L. (2007). Application of 2-hydroxyethyl methacrylate polymers in controlled release of 5-aminosalicylic acid as a colon-specific drug. *Journal of Polymer Research*, 14 (3), 207-213.
- Baker, D. C., Horton, D. & Tindall, C. G. (1972). Large-scale preparation of D-allose: observations on the stereoselectivity of the reduction of 1, 2: 5, 6-di-O-isopropylidene- α -D-ribo-hexofuranos-3-ulose hydrate. *Carbohydrate research*, 24 (1), 192-197.
- Benjamin, S. & Spener, F. (2009). Conjugated linoleic acids as functional food: an insight into their health benefits. *Nutrition & Metabolism*, 6 (1), 36.
- Boncler, M., Róźalski, M., Krajewska, U., Podsędek, A. & Watala, C. (2014). Comparison of prestoblue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells. *Journal of pharmacological and toxicological methods*, 69 (1), 9-16.
- Cai, Q. X., Zhu, K. J., Chen, D. & Gao, L. P. (2003). Synthesis, characterization and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride – P(CBFAS). *European Journal of Pharmaceutics and Biopharmaceutics*, 55 (2), 203-208.
- Calder, P. C. (2006). n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *The American journal of clinical nutrition*, 83 (6), S1505-1519S.
- Campregher, C., Luciani, M. G., Biesenbach, P., Evstatiev, R., Lyakhovich, A. & Gasche, C. (2010). The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. *Inflammatory bowel diseases*, 16 (4), 576-582.
- Carceller, E., Salas, J., Merlos, M., Giral, M., Ferrando, R., Escamilla, I., Ramis, J., García-Rafanell, J. & Forn, J. (2001). Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. *Journal of medicinal chemistry*, 44 (18), 3001-3013.
- Cassani, J., Luna, H., Navarro, A. & Castillo, E. (2007). Comparative esterification of phenylpropanoids versus hydrophenylpropanoids acids catalyzed by lipase in organic solvent media. *Electronic Journal of Biotechnology*, 10 (4), 508-513.
- Chanwitheesuk, A., Teerawutgulrag, A., Kilburn, J. D. & Rakariyatham, N. (2007). Antimicrobial gallic acid from *Caesalpinia mimosoides* Lamk. *Food Chemistry*, 100 (3), 1044-1048.
- Charlier, C. & Michaux, C. (2003). Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. *European journal of medicinal chemistry*, 38 (7), 645-659.
- Chen, X., Hui, L., Foster, D. A. & Drain, C. M. (2004). Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells. *Biochemistry*, 43 (34), 10918-10929.

- Clerici, C., Gentili, G., Boschetti, E., Santucci, C., Aburbah, A. G., Natalini, B., Pellicciari, R. & Morelli, A. (1994). Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery. *Digestive diseases and sciences*, 39 (12), 2601-2606.
- Couto, D., Ribeiro, D., Freitas, M., Gomes, A., Lima, J. L. & Fernandes, E. (2010). Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine. *Redox Report*, 15 (6), 259-267.
- Davaran, S., Rashidi, M. R., Hanaee, J., Khani, A., Mahkam, M. & Hashemi, M. (2006). Synthesis and degradation characteristics of polyurethanes containing azo derivatives of 5-amino salicylic acid. *Journal of bioactive and compatible polymers*, 21 (4), 315-326.
- Davis, B. G. & Robinson, M. A. (2002). Drug delivery systems based on sugar-macromolecule conjugates. *Current Opinion in Drug Discovery and Development*, 5 (2), 279-288.
- Desreumaux, P. & Ghosh, S. (2006). Review article: mode of action and delivery of 5-aminosalicylic acid—new evidence. *Alimentary pharmacology & therapeutics*, 24 (s1), 2-9.
- Douglas L. Marshall & Bullerman, L. B. (1994). Antimicrobial properties of sucrose fatty acid esters. *Carbohydrate polyesters as fat substitutes*, 62 (149).
- Ducret, A., Giroux, A., Trani, M. & Lortie, R. (1996). Characterization of enzymatically prepared biosurfactants. *Journal of the American Oil Chemists' Society*, 73 (1), 109-113.
- El-Haggag, R., Abdel-Rasheed, O. A., Nasr, T., Ali, H. I., Goudah, A. & Abotaleb, N. (2014). Synthesis, evaluation and molecular docking studies for the anti-inflammatory activity of novel 8-substituted-7-benzoyloxy-4-methyl-6-nitrocoumarin derivatives. *African Journal of Pharmacy and Pharmacology*, 8 (48), 1213-1227.
- Field, C. J., Blewett, H. H., Proctor, S. & Vine, D. (2009). Human health benefits of vaccenic acid. *Applied Physiology, Nutrition, and Metabolism*, 34 (5), 979-991.
- Fitscher, B., Elsing, C., Riedel, H.-D., Gorski, J. & Stremmel, W. (1996). Protein-mediated facilitated uptake processes for fatty acids, bilirubin, and other amphipathic compounds. *Experimental Biology and Medicine*, 212 (1), 15-23.
- Freeman, H. J. (2012). Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates. *Clinical medicine insights. Gastroenterology*, 5 (77).
- Friend, D. R. (1991). Colon-specific drug delivery. *Advanced drug delivery reviews*, 7 (1), 149-199.

- Friend, D. R. (2005). New oral delivery systems for treatment of inflammatory bowel disease. *Advanced drug delivery reviews*, 57 (2), 247-265.
- Gautam, R., Jachak, S. M., Kumar, V. & Mohan, C. G. (2011). Synthesis, biological evaluation and molecular docking studies of stellatin derivatives as cyclooxygenase (COX-1, COX-2) inhibitors and anti-inflammatory agents. *Bioorganic & medicinal chemistry letters*, 21 (6), 1612-1616.
- Giannini, E., Kane, S., Testa, R. & Savarino, V. (2005). 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for 'best evidence'? *Digestive and liver disease*, 37 (10), 723-731.
- Gil, A. (2002). Polyunsaturated fatty acids and inflammatory diseases. *Biomedicine & pharmacotherapy*, 56 (8), 388-396.
- Gilbert, N. C., Bartlett, S. G., Waight, M. T., Neau, D. B., Boeglin, W. E., Brash, A. R. & Newcomer, M. E. (2011). The structure of human 5-lipoxygenase. *Science*, 331 (6014), 217-219.
- Gruner, S. A., Kéri, G., Schwab, R., Venetianer, A. & Kessler, H. (2001). Sugar amino acid containing somatostatin analogues that induce apoptosis in both drug-sensitive and multidrug-resistant tumor cells. *Organic letters*, 3 (23), 3723-3725.
- Han, S.-Y. & Kim, Y.-A. (2004). Recent development of peptide coupling reagents in organic synthesis. *Tetrahedron*, 60 (11), 2447-2467.
- Hanauer, S. B. (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflammatory bowel diseases*, 12 (5), S3-S9.
- Hann, R. M., Ness, A. & Hudson, C. (1944). Diacetone xylitol (2, 3, 4, 5-di-isopropylidene-D, L-xylitol). *Journal of the American Chemical Society*, 66 (1), 73-76.
- Hartinger, C. G., Nazarov, A. A., Ashraf, S. M., Dyson, P. J. & Keppler, B. K. (2008). Carbohydrate-metal complexes and their potential as anticancer agents. *Current medicinal chemistry*, 15 (25), 2574-2591.
- Hegazy, G. H. & Ali, H. I. (2012). Design, synthesis, biological evaluation, and comparative Cox1 and Cox2 docking of p-substituted benzylideneamino phenyl esters of ibuprofenic and mefenamic acids. *Bioorganic & medicinal chemistry*, 20 (3), 1259-1270.
- Hofseth, L. J. & Ying, L. (2006). Identifying and defusing weapons of mass inflammation in carcinogenesis. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1765 (1), 74-84.
- Hua, Z., Kimura, G., Ito, Y., Mawatari, S., Shimokawa, T., Yoshikawa, H., Yoshikawa, Y. & Takada, K. (1999). Technology to obtain sustained release characteristics of drugs after delivered to the colon. *Journal of drug targeting*, 6 (6), 439-448.

- Huber, K., Martin, C. & Hardy, J. (2005). My Favorite Protein: Cyclooxygenase.
- Jacob, J. N. & Tazawa, M. J. (2012). Glucose–aspirin: Synthesis and in vitro anti-cancer activity studies. *Bioorganic & medicinal chemistry letters*, 22 (9), 3168-3171.
- Jiang, Y. & Kuang, C. (2009). A new convenient access to highly functionalized (E)-2-arylvinyl bromides. *Journal of Chemical Sciences*, 121 (6), 1035-1040.
- Jung, Y. J., Lee, J. S., Kim, H. H., Kim, Y. T. & Kim, Y. M. (1998). Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. *Archives of pharmacal research*, 21 (2), 179-186.
- Jung, Y. J., Lee, J. S. & Kim, Y. M. (2001). Colon-specific prodrugs of 5-aminosalicylic acid: Synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. *Journal of pharmaceutical sciences*, 90 (11), 1767-1775.
- Kabara, J. J., Swieczkowski, D. M., Conley, A. J. & Truant, J. P. (1972). Fatty acids and derivatives as antimicrobial agents. *Antimicrobial agents and chemotherapy*, 2 (1), 23-28.
- Kapetanovic, I. (2008). Computer-aided drug discovery and development (CADD): in silico-chemico-biological approach. *Chemico-biological interactions*, 171 (2), 165-176.
- Kenawy, E.-R., Al-Deyab, S. S. & El-Newehy, M. H. (2010). Controlled release of 5-Aminosalicylic acid (5-asa) from new biodegradable polyurethanes. *Molecules*, 15 (4), 2257-2268.
- Khan, A. T. & Musawwer Khan, M. (2010). A simple and convenient synthetic protocol for O-isopropylideneation of sugars using bromodimethylsulfonium bromide (BDMS) as a catalyst. *Carbohydrate Research*, 345 (1), 154-159.
- Khandanlou, R., Ahmad, M. B., Shameli, K., Saki, E. & Kalantari, K. (2014). Studies on Properties of Rice Straw/Polymer Nanocomposites Based on Polycaprolactone and Fe₃O₄ Nanoparticles and Evaluation of Antibacterial Activity. *International journal of molecular sciences*, 15 (10), 18466-18483.
- Kitahara, T., Koyama, N., Matsuda, J., Aoyama, Y., Hirakata, Y., Kamihira, S., Kohno, S., Nakashima, M. & Sasaki, H. (2004). Antimicrobial activity of saturated fatty acids and fatty amines against methicillin-resistant *Staphylococcus aureus*. *Biological & pharmaceutical bulletin*, 27 (9), 1321-1326.
- Kobayashi, T., Ehara, T., Mizuoka, T. & Adachi, S. (2010). Efficient synthesis of 6-O-palmitoyl-1, 2-O-isopropylidene- α -D-glucopyranose in an organic solvent system by lipase-catalyzed esterification. *Biotechnology letters*, 32 (11), 1679-1684.
- Kohane, D. S., Lipp, M., Kinney, R. C., Anthony, D. C., Louis, D. N., Lotan, N. & Langer, R. (2002). Biocompatibility of lipid-protein-sugar particles containing

bupivacaine in the epineurium. *Journal of biomedical materials research*, 59 (3), 450-459.

- Kowti, R., Harsha, R., Ahmed, M., Hareesh, A., Thammanna Gowda, S., Dinesha, R., Satish Kumar, B. & Irfan Ali, M. (2010). Antimicrobial activity of ethanol extract of leaf and flower of *Spathodea campanulata* P. Beauv. *Research Journal of Pharmaceutical, Biological and Chemical Science*, 3 (1), 691-8.
- Kuehl, G. E., Lampe, J. W., Potter, J. D. & Bigler, J. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. *Drug metabolism and disposition*, 33 (7), 1027-1035.
- Kukol, A. 2008. *Molecular modeling of proteins*, Springer.
- Kwakman, P. H. & Zaat, S. A. (2012). Antibacterial components of honey. *IUBMB life*, 64 (1), 48-55.
- Lengauer, T. & Rarey, M. (1996). Computational methods for biomolecular docking. *Current opinion in structural biology*, 6 (3), 402-406.
- Leong, S. W., Faudzi, S. M. M., Abas, F., Aluwi, M. F. F. M., Rullah, K., Wai, L. K., Bahari, M. N. A., Ahmad, S., Tham, C. L. & Shaari, K. (2014). Synthesis and SAR Study of Diarylpentanoid Analogues as New Anti-Inflammatory Agents. *Molecules*, 19 (10), 16058-16081.
- Li, Y., Chen, X. G., Liu, N., Liu, C. S., Liu, C. G., Meng, X. H., Yu, L. J. & Kenedy, J. F. (2007). Physicochemical characterization and antibacterial property of chitosan acetates. *Carbohydrate polymers*, 67 (2), 227-232.
- Lipták, A., Borbás, A. & Bajza, I. 2007. Protecting Group Manipulation in Carbohydrate Synthesis, *Comprehensive Glycoscience*. Elsevier BV.
- Liu, J., Gray, W. D., Davis, M. E. & Luo, Y. (2012). Peptide-and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. *Interface focus*, rfs20120009.
- Lopez, A. & Peyrin-Biroulet, L. (2012). 5-Aminosalicylic acid and chemoprevention: does it work? *Digestive diseases (Basel, Switzerland)*, 31 (2), 248-253.
- Lu, W., Navidpour, L. & Taylor, S. D. (2005). An expedient synthesis of benzyl 2, 3, 4-tri-O-benzyl- β -D-glucopyranoside and benzyl 2, 3, 4-tri-O-benzyl- β -D-mannopyranoside. *Carbohydrate research*, 340 (6), 1213-1217.
- Ly, K. A., Milgrom, P. & Rothen, M. (2008). The Potential of Dental-Protective Chewing Gum in Oral Health Interventions. *The Journal of the American Dental Association*, 139 (5), 553-563.
- Magda, A.-A., Abdel-Aziz, N. I., Alaa, A.-M., El-Azab, A. S., Asiri, Y. A. & Eltahir, K. E. (2011). Design, synthesis, and biological evaluation of substituted hydrazone

- and pyrazole derivatives as selective COX-2 inhibitors: molecular docking study. *Bioorganic & medicinal chemistry*, 19 (11), 3416-3424.
- Mahkam, M., Doostie, L. & Siadat, S. R. (2006). Synthesis and characterization of acrylic type hydrogels containing azo derivatives of 5-amino salicylic acid for colon-specific drug delivery. *Inflammopharmacology*, 14 (1-2), 72-75.
- Mahmmod, M. K. (2008). Synthesis of the new carbohydrate Ibuprofen ester as possible prodrug. *Journal of kerbala University*, 6 (2), 4-10.
- Mandal, S., Verma, P. R., Mukhopadhyay, B. & Gupta, P. (2011). Organoiridium complexes: efficient catalysts for the formation of sugar acetals and ketals. *Carbohydrate research*, 346 (13), 2007-2010.
- Marshall, G. R. (1987). Computer-aided drug design. *Annual review of pharmacology and toxicology*, 27 (1), 193-213.
- Maugard, T., Boulonne, M., Rejasse, B. & Legoy, M. D. (2001). Enzymatic synthesis of water-soluble derivatives of salicylic acid in organic media. *Biotechnology letters*, 23 (12), 989-993.
- Mclaren, A. C., Mclaren, S. G. & Smeltzer, M. (2006). Xylitol and glycine fillers increase permeability of PMMA to enhance elution of daptomycin. *Clinical orthopaedics and related research*, 451 (25-28).
- Mellou, F., Loutrari, H., Stamatis, H., Roussos, C. & Kolisis, F. N. (2006). Enzymatic esterification of flavonoids with unsaturated fatty acids: effect of the novel esters on vascular endothelial growth factor release from K562 cells. *Process Biochemistry*, 41 (9), 2029-2034.
- Meng, X.-Y., Zhang, H.-X., Mezei, M. & Cui, M. (2011). Molecular docking: a powerful approach for structure-based drug discovery. *Current computer-aided drug design*, 7 (2), 146.
- Midland, M. M., Beck, J. J., Peters, J. L., Rennels, R. A. & Asirwatham, G. (1994). Synthesis and Conformational Analysis of 1, 2: 3, 4-Di-O-isopropylidene-alpha-D-galactopyranose: A Nuclear Magnetic Resonance and Molecular Modeling Experiment. *Journal of chemical education*, 71 (10), 897.
- Mizuma, T., Ohta, K., Hayashi, M. & Awazu, S. (1992). Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs. *Biochemical pharmacology*, 43 (9), 2037-2039.
- Mohammed, A. I., Mansoor, N. H. & Mohammed, J. H. (2013). Copper (I) Catalyzed Synthesis and Antibacterial activity of 1, 2, 3-Triazoles Based on D-Fructose. *Kerbala Journal of Pharmaceutical Sciences*, 6 (179-195).
- Montalbetti, C. A. & Falque, V. (2005). Amide bond formation and peptide coupling. *Tetrahedron*, 61 (46), 10827-10852.

- Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K. & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *Journal of computational chemistry*, 19 (14), 1639-1662.
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of immunological methods*, 65 (1), 55-63.
- Muraoka, M., Kimura, G., Zhaopeng, H. & Takada, K. (1998). [Ulcerative colitis--colon delivery of 5-aminosalicylic acid]. *Nihon rinsho. Japanese journal of clinical medicine*, 56 (3), 788-794.
- Noaman, N. H., Fattah, A., Khaleafa, M. & Zaky, S. H. (2004). Factors affecting antimicrobial activity of *Synechococcus leopoliensis*. *Microbiological research*, 159 (4), 395-402.
- Nobilis, M., Vybiralova, Z., Sladkova, K., Lisa, M., Holčapek, M. & Květina, J. (2006). High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. *Journal of chromatography A*, 1119 (1), 299-308.
- Nobmann, P., Smith, A., Dunne, J., Henehan, G. & Bourke, P. (2009). The antimicrobial efficacy and structure activity relationship of novel carbohydrate fatty acid derivatives against *Listeria* spp. and food spoilage microorganisms. *International journal of food microbiology*, 128 (3), 440-445.
- Nordin, M., Asyikin, N., Buang, N. A. & Ahmad, S. (1998). A kinetic study on the esterification of palmitic acid in methanol. *Pertanika Journal of Science & Technology*, 6 (1), 71-79.
- Okabe, S., Suganuma, M., Tada, Y., Ochiai, Y., Sueoka, E., Kohya, H., Shibata, A., Takahashi, M., Mizutani, M. & Matsuzaki, T. (1999). Disaccharide Esters Screened for Inhibition of Tumor Necrosis Factor- α Release Are New Anti-cancer Agents. *Japanese journal of cancer research*, 90 (6), 669-676.
- Paleta, O., Dlouhá, I., Kaplánek, R., Kefurt, K. & Kodíček, M. (2002). Novel amphiphilic fluoroalkylated derivatives of xylitol, d-glucose and d-galactose for medical applications: hemocompatibility and co-emulsifying properties. *Carbohydrate research*, 337 (24), 2411-2418.
- Palkar, M. B., Singhai, A. S., Ronad, P. M., Vishwanathswamy, A., Boreddy, T. S., Veerapur, V. P., Shaikh, M. S., Rane, R. A. & Karpoornath, R. (2014). Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. *Bioorganic & medicinal chemistry*, 22 (10), 2855-2866.
- Pastorini, E., Locatelli, M., Simoni, P., Roda, G., Roda, E. & Roda, A. (2008). Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-

- aminosalicylic acid in human plasma. *Journal of Chromatography B*, 872 (1), 99-106.
- Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaili, L., Refouvelet, B., Pellequer, Y. & Lamprecht, A. (2007). 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. *Journal of controlled release*, 123 (3), 211-218.
- Pinto, T. A., Hrdina, R., Kirsch, G., Campos, A. M., Rodrigues, L. M. & Esteves, A. P. (2012). Synthesis of esters derived from 2, 3, 4-tri-O-benzyl-alpha-D-methylglucoside. 2012), 1-8.
- Pouillart, P., Douillet, O., Scappini, B., Gozzini, A., Santini, V., Grossi, A., Pagliai, G., Strippoli, P., Rigacci, L. & Ronco, G. (1999). Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. *European journal of pharmaceutical sciences*, 7 (2), 93-106.
- Punchard, N., Greenfield, S. & Thompson, R. (1992). Mechanism of action of 5-aminosalicylic acid. *Mediators of inflammation*, 1 (3), 151-165.
- Quan, J., Chen, Z., Han, C. & Lin, X. (2007a). The synthesis of amphipathic prodrugs of 1, 2-diol drugs with saccharide conjugates by high regioselective enzymatic protocol. *Bioorganic & medicinal chemistry*, 15 (4), 1741-1748.
- Quan, J., Xu, J.-M., Liu, B.-K., Zheng, C.-Z. & Lin, X.-F. (2007b). Synthesis and characterization of drug-saccharide conjugates by enzymatic strategy in organic media. *Enzyme and Microbial Technology*, 41 (6), 756-763.
- Rajesh, Y., O.P. Mahatma (2011). Ester Prodrug of 5-Aminosalicylic Acid for Colon Specific Drug Delivery: Synthesis, Kinetics, Hydrolysis and Stabilities studies. *Journal of pharmaceutical science & research*, 3(1) (966-972).
- Ravn, H. & Brimer, L. (1988). Structure and antibacterial activity of plantamajoside, a caffeic acid sugar ester from *Plantago major* subs *major*. *Phytochemistry*, 27 (11), 3433-3437.
- Reynolds, P., Middleton, S., Shorthouse, M. & Hunter, J. (1995). The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system. *Alimentary pharmacology & therapeutics*, 9 (5), 491-495.
- Ritland, S. R., Leighton, J. A., Hirsch, R. E., Morrow, J. D., Weaver, A. L. & Gendler, S. J. (1999). Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: Lack of efficacy against nascent adenomatous polyps in the ApcMin mouse. *Clinical cancer research*, 5 (4), 855-863.
- Rong, Y. W., Zhang, Q. H., Wang, W. & Li, B. L. (2014). A Simple and Clean Method for O-Isopropylideneation of Carbohydrates. *Notes*, 35 (7), 2165.

- Roynette, C. E., Calder, P. C., Dupertuis, Y. M. & Pichard, C. (2004). n-3 Polyunsaturated fatty acids and colon cancer prevention. *Clinical Nutrition*, 23 (2), 139-151.
- Rufino, A. R., Biaggio, F. C., Santos, J. C. & De Castro, H. F. (2009). Chemoenzymatic synthesis: a strategy to obtain xylitol monoesters. *Journal of chemical technology and biotechnology*, 84 (7), 957-960.
- Samy, R. P. & Ignacimuthu, S. (2000). Antibacterial activity of some folklore medicinal plants used by tribals in Western Ghats of India. *Journal of Ethnopharmacology*, 69 (1), 63-71.
- Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. *New England Journal of Medicine*, 317 (26), 1625-1629.
- Seeliger, D. & De Groot, B. L. (2010). Conformational transitions upon ligand binding: holo-structure prediction from apo conformations. *PLoS Comput Biol*, 6 (1), e1000634.
- Selvam, C., Jachak, S. M., Thilagavathi, R. & Chakraborti, A. K. (2005). Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. *Bioorganic & medicinal chemistry letters*, 15 (7), 1793-1797.
- Shiff, S. J., Shivaprasad, P. & Santini, D. L. (2003). Cyclooxygenase inhibitors: drugs for cancer prevention. *Current opinion in pharmacology*, 3 (4), 352-361.
- Shukla, R. K. & Tiwari, A. (2011). Carbohydrate molecules: an expanding horizon in drug delivery and biomedicine. *Critical Reviews™ in Therapeutic Drug Carrier Systems*, 28 (3), 255-292.
- Singh, S., Nair, V., Jain, S. & Gupta, Y. (2008). Evaluation of anti-inflammatory activity of plant lipids containing alpha-linolenic acid. *Indian journal of experimental biology*, 46 (6), 453.
- Singh, S., Taneja, M. & Majumdar, D. K. (2007). Biological activities of *Ocimum sanctum* L. fixed oil-An overview. *Indian journal of experimental biology*, 45 (5), 403.
- Sinha, V. & Kumria, R. (2001). Polysaccharides in colon-specific drug delivery. *International journal of pharmaceuticals*, 224 (1), 19-38.
- Slessor, K. & Tracey, A. (1969). 1, 2: 5, 6-Di-O-isopropylidene-D-hexofuranoses and their 3-keto derivatives. *Canadian Journal of Chemistry*, 47 (21), 3989-3995.
- Smith, A., Nobmann, P., Henahan, G., Bourke, P. & Dunne, J. (2008). Synthesis and antimicrobial evaluation of carbohydrate and polyhydroxylated non-carbohydrate fatty acid ester and ether derivatives. *Carbohydrate research*, 343 (15), 2557-2566.

- Sninsky, C. A., Cort, D. H., Shanahan, F., Powers, B. J., Sessions, J. T., Pruitt, R. E., Jacobs, W. H., Lo, S. K., Targan, S. R. & Cerda, J. J. (1991). Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. *Annals of internal medicine*, 115 (5), 350-355.
- Soliman, M. H. & Mohamed, G. G. (2013). Cr (III), Mn (II), Fe (III), Co (II), Ni (II), Cu (II) and Zn (II) new complexes of 5-aminosalicylic acid: spectroscopic, thermal characterization and biological activity studies. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 107 (8-15).
- Soni, K. & Sah, A. K. (2014). The synthesis of amino acid derived glycoconjugates and the investigation of their anti-inflammatory and analgesic properties. *RSC Advances*, 4 (12), 6068-6073.
- Sorg, B. L., Hull, W. E., Kliem, H.-C., Mier, W. & Wiessler, M. (2005). Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy. *Carbohydrate research*, 340 (2), 181-189.
- Stamatis, H., Sereti, V. & Kolisis, F. (1999). Studies on the enzymatic synthesis of lipophilic derivatives of natural antioxidants. *Journal of the American Oil Chemists' Society*, 76 (12), 1505-1510.
- Stamatis, H., Sereti, V. & Kolisis, F. (2001). Enzymatic synthesis of hydrophilic and hydrophobic derivatives of natural phenolic acids in organic media. *Journal of Molecular Catalysis B: Enzymatic*, 11 (4), 323-328.
- Stolfi, C., Fina, D., Caruso, R., Caprioli, F., Sarra, M., Fantini, M. C., Rizzo, A., Pallone, F. & Monteleone, G. (2008). Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. *Biochemical Pharmacology*, 75 (3), 668-676.
- Takaya, T., Sawada, K., Suzuki, H., Funaoka, A., Matsuda, K.-I. & Takada, K. (1997). Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. *Journal of drug targeting*, 4 (5), 271-276.
- Tashiro, T., Inaba, M. & Sakurai, Y. (1982). Reduction of lethal toxicity of chloroethylnitrosoureas by sugar alcohols without loss of antitumor activity. *Cancer chemotherapy and pharmacology*, 8 (2), 183-188.
- Travis, S. (2002). Which 5-ASA? *Gut*, 51 (4), 548-549.
- Travis, S. & Jewell, D. (1994). Salicylates for ulcerative colitis—their mode of action. *Pharmacology & therapeutics*, 63 (2), 135-161.
- Tromm, A., Griga, T. & May, B. (1998). Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. *Hepato-gastroenterology*, 46 (30), 3124-3135.

- Trott, O. & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of computational chemistry*, 31 (2), 455-461.
- Tursi, A., Joseph, R. E. & Streck, P. (2011). Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. *Digestive diseases and sciences*, 56 (11), 3112-3121.
- Uhrig, R. K., Picard, M. A., Beyreuther, K. & Wiessler, M. (2000). Synthesis of antioxidative and anti-inflammatory drugs glucoconjugates. *Carbohydrate research*, 325 (1), 72-80.
- Vareed, S. K., Reddy, M. K., Schutzki, R. E. & Nair, M. G. (2006). Anthocyanins in *Cornus alternifolia*, *Cornus controversa*, *Cornus kousa* and *Cornus florida* fruits with health benefits. *Life Sciences*, 78 (7), 777-784.
- Vilar, S., Cozza, G. & Moro, S. (2008). Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. *Current topics in medicinal chemistry*, 8 (18), 1555-1572.
- Wallace, A. C., Laskowski, R. A. & Thornton, J. M. (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein engineering*, 8 (2), 127-134.
- Watanabe, T., Katayama, S., Matsubara, M., Honda, Y. & Kuwahara, M. (2000). Antibacterial carbohydrate monoesters suppressing cell growth of *Streptococcus mutans* in the presence of sucrose. *Current microbiology*, 41 (3), 210-213.
- Waterman, E. & Lockwood, B. (2007). Active components and clinical applications of olive oil. *Alternative medicine review: a journal of clinical therapeutic*, 12 (4), 331-342.
- William, C., Haber, G. & Aquino, J. (1987). Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using ^{99m}Tc-labeled 5-ASA suppositories. *Digestive diseases and sciences*, 32 (12), S71-S75.
- Williams, C., Panaccione, R., Ghosh, S. & Rioux, K. (2011). Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. *Therapeutic advances in gastroenterology*, 4 (237-48).
- Williams, C. M. (2000). Dietary fatty acids and human health. *Annales de Zootechnie*, 49 (3), 165-180.
- Yadav, M. G., Vadgama, R. N., Odaneth, A. A. & Lali, A. M. 2015. Enzymatic Synthesis of Sugar Fatty Acid Ester. *International Conference on Sustainable Chemistry & Engineering*. Hotel Lalit, Mumbai.
- Yang, Z. & Huang, Z.-L. (2012). Enzymatic synthesis of sugar fatty acid esters in ionic liquids. *Catalysis Science & Technology*, 2 (9), 1767-1775.

- Yang, Z., Ye, X., Wu, Q., Wu, K. & Fan, D. (2014). A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease. *International Journal of Surgery*, 12 (5), 516-522.
- Zhang, S. 2011. Computer-aided drug discovery and development. *Drug Design and Discovery*. Springer.
- Zhao, G., Etherton, T. D., Martin, K. R., Heuvel, J. P. V., Gillies, P. J., West, S. G. & Kris-Etherton, P. M. (2005). Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. *Biochemical and biophysical research communications*, 336 (3), 909-917.
- Zheng, C. J., Yoo, J.-S., Lee, T.-G., Cho, H.-Y., Kim, Y.-H. & Kim, W.-G. (2005). Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. *FEBS letters*, 579 (23), 5157-5162.
- Zheng, G., Graham, A., Shibata, M., Missert, J. R., Oseroff, A. R., Dougherty, T. J. & Pandey, R. K. (2001). Synthesis of β -galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy. *The Journal of organic chemistry*, 66 (26), 8709-8716.
- Zhu, Y.-P., Su, Z.-W. & Li, C.-H. (1989). Growth-inhibition effects of oleic acid, linoleic acid, and their methyl esters on transplanted tumors in mice. *Journal of the National Cancer Institute*, 81 (17), 1302-1306.
- Zou, M., Okamoto, H., Cheng, G., Hao, X., Sun, J., Cui, F. & Danjo, K. (2005). Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems. *European journal of pharmaceutics and biopharmaceutics*, 59 (1), 155-160.
- Zoumpantioti, M., Merianou, E., Karandreas, T., Stamatis, H. & Xenakis, A. (2010). Esterification of phenolic acids catalyzed by lipases immobilized in organogels. *Biotechnology letters*, 32 (10), 1457-1462.